Please login to the form below

Not currently logged in
Email:
Password:

Clinigen appoints Shaun Chilton as COO of services division

Former KnowledgePoint360 Group president and MD will head both Keats Healthcare and Clinigen GAP

Clinigen, the UK-based specialty pharmaceutical and pharma services provider, has appointed Shaun Chilton to the newly-created role of chief operating officer of the group's services division.

Chilton joins from healthcare information supplier KnowledgePoint360 Group, where he was both president and managing director.

In his new role he will head both Clinigen's clinical trial supply business Keats Healthcare and Clinigen GAP, a specialist provider of early- and late-lifecycle prescription drugs, streamlining the two businesses.

Keats Healthcare, which was acquired by Clinigen in 2010, is currently being rebranded as Clinigen CTS.

Commenting on the appointment, Chilton said: “Keats Healthcare and Clinigen GAP are already successful businesses providing standalone services, but they are highly complementary and synergies between the two companies make their combination into a services division compelling.”

He joins the company from KnowledgePoint360 Group, a supplier of healthcare information, and prior to that held positions in sales and marketing at both Pfizer and Sanofi.

Peter George, CEO of Clinigen, said: “Shaun has a strong track record of building and leading high-performance sales and operational teams; driving commercial growth from international businesses; developing highly effective strategies, including major restructurings; and executing new strategies to deliver business goals, improve profitability and meet challenging targets.”

23rd January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics